Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Coukos

Showing results (291-300 of 355) with videos related to

Pageof 36
Sort By:
Cell Reports. Medicine|March 5, 2021
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoeditingJulien Schmidt, Angela R Smith, Morgane Magnin, et al.
Nature Immunology|September 14, 2023
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8<sup>+</sup> T cell exhaustionLaure Tillé, Daniela Cropp, Mélanie Charmoy, et al.
Molecular Therapy. Oncology|December 15, 2025
Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editingMorteza Hafezi, Raphael Genolet, Leila Hadadi, et al.
Frontiers in Immunology|August 24, 2019
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three PatientsMichal Bassani-Sternberg, Antonia Digklia, Florian Huber, et al.
Cancer Immunology, Immunotherapy : CII|January 10, 2018
Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapyXiaopeng Yuan, Mingjuan Yang, Xiang Chen, et al.
Nature Communications|November 6, 2021
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitopeHakimeh Ebrahimi-Nik, Marmar Moussa, Ryan P Englander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Integrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyBradley J Monk, Andrea Facciabene, William E Brady, et al.
Frontiers in Immunology|February 5, 2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024Gisela Maria Suárez Formigo, Zaima Mazorra, Cinthia Olexen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2006
microRNAs exhibit high frequency genomic alterations in human cancerLin Zhang, Jia Huang, Nuo Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive TherapyEmese Zsiros, Priyanka Duttagupta, Denarda Dangaj, et al.
Pageof 36

Showing results (291-300 of 355) with videos related to

Sort By:
Pageof 36
Cell Reports. Medicine|March 5, 2021
Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoeditingJulien Schmidt, Angela R Smith, Morgane Magnin, et al.
Nature Immunology|September 14, 2023
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8<sup>+</sup> T cell exhaustionLaure Tillé, Daniela Cropp, Mélanie Charmoy, et al.
Molecular Therapy. Oncology|December 15, 2025
Highly efficient gene knockout in tumor-infiltrating lymphocytes by adenine base editingMorteza Hafezi, Raphael Genolet, Leila Hadadi, et al.
Frontiers in Immunology|August 24, 2019
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three PatientsMichal Bassani-Sternberg, Antonia Digklia, Florian Huber, et al.
Cancer Immunology, Immunotherapy : CII|January 10, 2018
Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapyXiaopeng Yuan, Mingjuan Yang, Xiang Chen, et al.
Nature Communications|November 6, 2021
Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitopeHakimeh Ebrahimi-Nik, Marmar Moussa, Ryan P Englander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Integrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyBradley J Monk, Andrea Facciabene, William E Brady, et al.
Frontiers in Immunology|February 5, 2026
Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024Gisela Maria Suárez Formigo, Zaima Mazorra, Cinthia Olexen, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2006
microRNAs exhibit high frequency genomic alterations in human cancerLin Zhang, Jia Huang, Nuo Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive TherapyEmese Zsiros, Priyanka Duttagupta, Denarda Dangaj, et al.
Pageof 36